This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Reports First Experimental Studies Combining Antibody-Drug Conjugate With Antibody-Directed Radiation Therapy For Pancreatic Cancer

SAN FRANCISCO, Jan. 24, 2011 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that combining antibody-directed drug and radionuclide therapeutics for pancreatic cancer improved efficacy in preclinical studies with minimal toxicity. Results from these investigations were presented at the 2011 Gastrointestinal Cancers Symposium. 

Two of the Company's proprietary humanized antibodies were involved in this research. Clivatuzumab, which selectively targets pancreatic cancer, has shown in preclinical and early clinical studies promising therapeutic activity when labeled with yttrium-90 (Y-90) and in combination with gemcitabine. hRS7 has been shown to internalize into cancer cells when bound to its receptor, EGP-1, or TROP-2, making it an attractive antibody for delivery of cytotoxic drugs.

Since TROP-2 has higher expression in lung, breast, prostate, ovarian, colorectal, pancreatic and cervical cancers than in normal tissues, the Company has previously conjugated SN-38, the active metabolite of irinotecan approved as a chemotherapeutic agent for metastatic colorectal cancer, to hRS7 for targeted treatment of cancer. In preclinical studies, hRS7-SN-38 has demonstrated potent therapeutic effects against lung cancer. (Please refer to the Company's press release at for more information). 

Using nude mice bearing human pancreatic cancer cells as a model, the goal of the current studies was to evaluate the possibility that hRS7-SN-38, at effective, yet non-toxic doses, could augment therapeutic responses with Y-90-labeled clivatuzumab tetraxetan. Clivatuzumab-SN-38 conjugate was also included in these evaluations.

Irinotecan, given at a dose that contained the same amount of SN-38 as the antibody-drug conjugates (ADC), was not effective in controlling tumor growth, while each ADC alone was able to inhibit tumor growth significantly compared to untreated animals. When ADC was combined with the radiolabeled antibody, time to progression (TTP) improved considerably and more animals were tumor-free.  Importantly, an effective ADC dose can be combined at the maximum tolerated dose (MTD) of Y-90 clivatuzumab tetraxetan with minimal additional toxicity.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs